Tags

Type your tag names separated by a space and hit enter

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Neurobiol Aging 2006; 27(9):1202-11NA

Abstract

We prospectively evaluated the diagnostic accuracy of cerebrospinal fluid (CSF)-beta-amyloid1-42 (Abeta42), -total-tau (tau) and -phosphorylated-tau181 (p-tau181) as measured by sandwich ELISAs in the clinical routine of a community state hospital to discriminate between patients with Alzheimer's disease (AD), healthy controls (HC), non-AD-dementias, a group composed of various psychiatric disorders (non-AD-dementias, mental diseases) and an age-matched random sample (RS) (total N=219). By comparing patients with AD to HC as reference, tau revealed sensitivity (sens)/specificity (spec) of 88%/80%, p-tau(181) 88%/80%, tau/Abeta42-ratio 81%/85% and phospho-tau(181)/Abeta42-ratio 81%/78%. Discriminative power between HC and all dementias under investigation was estimated lower for tau (78%/77%) and p-tau(181) (73%/79%). Relative to patients with AD, ROC analysis for the RS revealed highest sens/spec for p-tau181 (79%/77%) and p-tau181/Abeta42 ratio (78%/75%). Differentiation between AD versus a group made of patients with various psychiatric disorders was optimised by using CSF-p-tau181 (80%/77%). Under clinical routine conditions current CSF-biomarkers show a substantial capacity to discriminate between AD and HC as reference and to mark off AD patients from RS and heterogeneous diagnostic groups composed of non-AD dementias and other psychiatric conditions. Despite a residual substantial overlap between the groups, we conclude that current CSF markers are well suited to support AD-related diagnostic procedures in every-day clinics.

Authors+Show Affiliations

Department of Psychiatry, Psychosomatics and Psychotherapy, Geriatric Psychiatry Research Group, University of Regensburg at the Bezirksklinikum, Universitätsstrasse 84, D-93053 Regensburg, Germany. bernd.ibach@klinik.uni-regensburg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Studies
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16085339

Citation

Ibach, Bernd, et al. "Cerebrospinal Fluid Tau and Beta-amyloid in Alzheimer Patients, Disease Controls and an Age-matched Random Sample." Neurobiology of Aging, vol. 27, no. 9, 2006, pp. 1202-11.
Ibach B, Binder H, Dragon M, et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging. 2006;27(9):1202-11.
Ibach, B., Binder, H., Dragon, M., Poljansky, S., Haen, E., Schmitz, E., ... Hajak, G. (2006). Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiology of Aging, 27(9), pp. 1202-11.
Ibach B, et al. Cerebrospinal Fluid Tau and Beta-amyloid in Alzheimer Patients, Disease Controls and an Age-matched Random Sample. Neurobiol Aging. 2006;27(9):1202-11. PubMed PMID: 16085339.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. AU - Ibach,Bernd, AU - Binder,Harald, AU - Dragon,Margarethe, AU - Poljansky,Stefan, AU - Haen,Ekkehard, AU - Schmitz,Eberhard, AU - Koch,Horst, AU - Putzhammer,Albert, AU - Kluenemann,Hans, AU - Wieland,Wolf, AU - Hajak,Goeran, Y1 - 2005/08/08/ PY - 2004/12/22/received PY - 2005/06/15/revised PY - 2005/06/16/accepted PY - 2005/8/9/pubmed PY - 2006/8/29/medline PY - 2005/8/9/entrez SP - 1202 EP - 11 JF - Neurobiology of aging JO - Neurobiol. Aging VL - 27 IS - 9 N2 - We prospectively evaluated the diagnostic accuracy of cerebrospinal fluid (CSF)-beta-amyloid1-42 (Abeta42), -total-tau (tau) and -phosphorylated-tau181 (p-tau181) as measured by sandwich ELISAs in the clinical routine of a community state hospital to discriminate between patients with Alzheimer's disease (AD), healthy controls (HC), non-AD-dementias, a group composed of various psychiatric disorders (non-AD-dementias, mental diseases) and an age-matched random sample (RS) (total N=219). By comparing patients with AD to HC as reference, tau revealed sensitivity (sens)/specificity (spec) of 88%/80%, p-tau(181) 88%/80%, tau/Abeta42-ratio 81%/85% and phospho-tau(181)/Abeta42-ratio 81%/78%. Discriminative power between HC and all dementias under investigation was estimated lower for tau (78%/77%) and p-tau(181) (73%/79%). Relative to patients with AD, ROC analysis for the RS revealed highest sens/spec for p-tau181 (79%/77%) and p-tau181/Abeta42 ratio (78%/75%). Differentiation between AD versus a group made of patients with various psychiatric disorders was optimised by using CSF-p-tau181 (80%/77%). Under clinical routine conditions current CSF-biomarkers show a substantial capacity to discriminate between AD and HC as reference and to mark off AD patients from RS and heterogeneous diagnostic groups composed of non-AD dementias and other psychiatric conditions. Despite a residual substantial overlap between the groups, we conclude that current CSF markers are well suited to support AD-related diagnostic procedures in every-day clinics. SN - 1558-1497 UR - https://www.unboundmedicine.com/medline/citation/16085339/Cerebrospinal_fluid_tau_and_beta_amyloid_in_Alzheimer_patients_disease_controls_and_an_age_matched_random_sample_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0197-4580(05)00186-7 DB - PRIME DP - Unbound Medicine ER -